Elena Mead
Overview
Explore the profile of Elena Mead including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
3743
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen L, Tayban K, Tomicich J, Buchholz T, Barzola M, Mead E, et al.
J Am Assoc Nurse Pract
. 2023 Aug;
PMID: 37646585
Implementation of a comprehensive point-of-care ultrasound (POCUS) program for nurse practitioners (NPs) and physician assistants (PAs) in an intensive care unit (ICU) setting improves their diagnostic and therapeutic skills and...
2.
Park J, Nath K, Devlin S, Sauter C, Palomba M, Shah G, et al.
Nat Med
. 2023 Jul;
29(7):1710-1717.
PMID: 37400640
In preclinical models, anakinra, an IL-1 receptor antagonist (IL-1Ra), reduced immune effector cell-associated neurotoxicity syndrome (ICANS) without compromising anti-CD19 chimeric antigen receptor (CAR) T-cell efficacy. We initiated a phase 2...
3.
Mahmood S, Riedell P, Feldman S, George G, Sansoterra S, Althaus T, et al.
Eur Heart J
. 2023 Mar;
44(22):2029-2042.
PMID: 36939851
Aims: Chimeric antigen receptor T-cell therapy (CAR-T) harnesses a patient's immune system to target cancer. There are sparse existing data characterizing death outcomes after CAR-T-related cardiotoxicity. This study examines the...
4.
Mailankody S, Devlin S, Landa J, Nath K, Diamonte C, Carstens E, et al.
N Engl J Med
. 2022 Sep;
387(13):1196-1206.
PMID: 36170501
Background: B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have generated responses in patients with advanced myeloma, but relapses are common. G protein-coupled receptor, class C, group 5,...
5.
Pennisi M, Sanchez-Escamilla M, Flynn J, Shouval R, Tomas A, Silverberg M, et al.
Blood Adv
. 2021 Aug;
5(17):3397-3406.
PMID: 34432870
Patients who develop chimeric antigen receptor (CAR) T-cell-related severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) exhibit hemodynamic instability and endothelial activation. The EASIX (Endothelial Activation...
6.
Gutierrez C, Brown A, May H, Beitinjaneh A, Stephens R, Rajendram P, et al.
Crit Care Med
. 2021 Jul;
50(1):81-92.
PMID: 34259446
Objectives: To report the epidemiology, treatments, and outcomes of adult patients admitted to the ICU after cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. Design: Retrospective cohort study. Setting:...
7.
Garcia-Recio M, Wudhikarn K, Pennisi M, Alonso-Trillo R, Flynn J, Shouval R, et al.
Transplant Cell Ther
. 2021 Mar;
27(3):233-240.
PMID: 33781518
CD19-targeted chimeric antigen receptor (CAR) T cells have shown excellent activity against relapsed and refractory (R/R) diffuse large B cell lymphoma (DLBCL). CAR T cell therapy is associated with early...
8.
Maus M, Alexander S, Bishop M, Brudno J, Callahan C, Davila M, et al.
J Immunother Cancer
. 2020 Dec;
8(2).
PMID: 33335028
Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients...
9.
Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz J, Purdon T, et al.
Blood Adv
. 2020 Aug;
4(15):3776-3787.
PMID: 32780846
Factors contributing to hematopoietic recovery following chimeric antigen receptor (CAR) T-cell therapy have not been well studied. In an analysis of 83 patients with hematologic malignancies treated with CAR T-cell...
10.
Wudhikarn K, Palomba M, Pennisi M, Garcia-Recio M, Flynn J, Devlin S, et al.
Blood Cancer J
. 2020 Aug;
10(8):79.
PMID: 32759935
CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for diffuse large B cell lymphoma (DLBCL). In addition to cytokine release syndrome (CRS) and immune effector cell-associated...